Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer

Biomaterials

Volumn 35, Issue 26, 2014, Pages 7610-7621

  Ju, Rui Jun ^a   Li, Xue Tao ^a   Shi, Ji Feng ^a   Li, Xiu Ying ^a   Sun, Meng Ge ^a   Zeng, Fan ^a   Zhou, Jia ^a   Liu, Lei ^a   Zhang, Cheng Xiang ^a   Zhao, Wei Yu ^a   Lu, Wan Liang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anticancer efficacy; Invasive breast cancer; Targeting epirubicin plus celecoxib liposomes; Vasculogenic mimicry channels

Indexed keywords

BIOLOGICAL MATERIALS; CELL DEATH; CHEMOTHERAPY; LIPOSOMES; MAMMALS; PEPTIDES; TUMORS; VIRUSES;

ANTICANCER EFFICACY; BREAST CANCER; BREAST CANCER CELLS; CELECOXIB; HUMAN BREAST CANCER; HUMAN IMMUNODEFICIENCY VIRUS; VASCULOGENIC; XENOGRAFTS IN NUDE MOUSE;

DISEASES;

CASPASE 10; CASPASE 8; CELECOXIB; EPHRIN RECEPTOR A2; EPIRUBICIN; FOCAL ADHESION KINASE; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOSOME; VASCULAR ENDOTHELIAL CADHERIN; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; PEPTIDE; PHOSPHATIDYLETHANOLAMINE; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BREAST CANCER; CIRCULATION TIME; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BREAST; BREAST NEOPLASMS; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOUSE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION;

HUMAN IMMUNODEFICIENCY VIRUS; MUS MUSCULUS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; EPIRUBICIN; FEMALE; HIV-1; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; PYRAZOLES; SULFONAMIDES;

EID: 84902553155     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.05.040     Document Type: Article

References (33)

1. Liu T., Sun B., Zhao X., Gu Q., Dong X., Yao Z., et al. HER2/neu expression correlates with vasculogenic mimicry in invasive breast carcinoma. JCell Mol Med 2013, 17:116-122.
2. Shirakawa K., Kobayashi H., Sobajima J., Hashimoto D., Shimizu A., Wakasugi H. Inflammatory breast cancer: vasculogenic mimicry and its hemodynamics of an inflammatory breast cancer xenograft model. Breast Cancer Res 2003, 5:136-139.
3. Kirschmann D.A., Seftor E.A., Hardy K.M., Seftor R.E., Hendrix M.J. Molecular pathways: vasculogenic mimicry in tumor cells: diagnostic and therapeutic implications. Clin Cancer Res 2012, 18:2726-2732.
4. Zhao N., Sun B.C., Sun T., Ma Y.M., Zhao X.L., Liu Z.Y., et al. Hypoxia-induced vasculogenic mimicry formation via VE-cadherin regulation by Bcl-2. Med Oncol 2012, 29:3599-3607.
5. Folberg R., Hendrix M.J., Maniotis A.J. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol 2000, 156:361-381.
6. Clemente M., Pérez-Alenza M.D., Illera J.C., Peña L. Histological, immunohistological, and ultrastructural description of vasculogenic mimicry in canine mammary cancer. Vet Pathol 2010, 47:265-274.
7. Hidema S., Tonomura Y., Date S., Nishimori K. Effects of protein transduction with intact myogenic transcription factors tagged with HIV-1 Tat-PTD (T-PTD) on myogenic differentiation of mouse primary cells. JBiosci Bioeng 2012, 113:5-11.
8. Mulligan J.M., Hill L.A., Deharo S., Irwin G., Boyle D., Keating K.E., et al. Identification and validation of an anthracycline/cyclophosphamide-based chemotherapy response assay in breast cancer. JNatl Cancer Inst 2014, 106:1-10.
9. Plosker G.L., Faulds D. Epirubicin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs 1993, 45:788-856.
10. Cowell I.G., Austin C.A. Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents. Int J Environ Res Public Health 2012, 9:2075-2091.
11. Kariya S., Ogawa Y., Nishioka A., Moriki T., Ohnishi T., Ito S., et al. Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients. Radiat Med 2005, 23:189-194.
12. Chow L.W., Tung S.Y., Ng T.Y., Im S.A., Lee M.H., Yip A.Y., et al. Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study. Expert Opin Investig Drugs 2013, 22:299-307.
13. Glynn S.A., Prueitt R.L., Ridnour L.A., Boersma B.J., Dorsey T.M., Wink D.A., et al. COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancer. BMC Cancer 2010, 10:1-12.
14. Spizzo G., Gastl G., Wolf D., Gunsilius E., Steurer M., Fong D., et al. Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival. Br J Cancer 2003, 88:574-578.
15. Hu M., Peluffo G., Chen H., Gelman R., Schnitt S., Polyak K. Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast. Proc Natl Acad Sci U S A 2009, 106:3372-3377.
16. Fan Y.Z., Sun W. Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy. World J Gastrointest Surg 2010, 2:117-127.
17. 2+ by amlodipine thus leading to an enhanced antitumor activity in leukemia. JControl Release 2006, 112:186-198.
18. Liu Y., Lu W.L., Guo J., Du J., Li T., Wu J.W., et al. Apotential target associated with both cancer and cancer stem cells: a combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. JControl Release 2008, 129:18-25.
19. Wang X.X., Li Y.B., Yao H.J., Ju R.J., Zhang Y., Li R.J., et al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials 2011, 32:5673-5687.
20. Matsumura Y., Maeda H. Anew concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
21. de la Fuente J.M., Berry C.C. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem 2005, 16:1176-1180.
22. Richard J.P., Melikov K., Brooks H., Prevot P., Lebleu B., Chernomordik L.V. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. JBiol Chem 2005, 280:15300-15306.
23. Kersemans V., Cornelissen B. Targeting the tumour: cell penetrating peptides for molecular imaging and radiotherapy. Pharmaceuticals 2010, 3:600-620.
24. Wang Z., Yu Y., Ma J., Zhang H., Zhang H., Wang X., et al. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. Mol Pharm 2012, 9:2646-2657.
25. Zhou J., Zhao W.Y., Ma X., Ju R.J., Li X.Y., Li N., et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 2013, 34:3626-3638.
26. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
27. Kostarelos K., Emfietzoglou D., Papakostas A., Yang W.H., Ballangrud A., Sgouros G., et al. Binding and interstitial penetration of liposomes within avascular tumor spheroids. Int J Cancer 2004, 112:713-721.
28. Lee S.L., Chang E.D., Na S.J., Kim J.S., An H.J., Ko Y.H., et al. Pseudocirrhosis of breast cancer metastases to the liver treated by chemotherapy. Cancer Res Treat 2014, 46:98-103.
29. Sun B., Zhang S., Zhao X., Zhang W., Hao X. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Int J Oncol 2004, 25:1609-1614.
30. De Lange Davies C., Müller H., Hagen I., Garseth M., Hjelstuen M.H. Comparison of extracellular matrix in human osteosarcomas and melanomas growing as xenografts, multicellular spheroids, and monolayer cultures. Anticancer Res 1997, 17:4317-4326.
31. Hess A.R., Seftor E.A., Gruman L.M., Kinch M.S., Seftor R.E., Hendrix M.J. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006, 5:228-233.
32. Hess A.R., Seftor E.A., Gardner L.M., Carles-Kinch K., Schneider G.B., Seftor R.E., et al. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001, 61:3250-3255.
33. Liu X.M., Zhang Q.P., Mu Y.G., Zhang X.H., Sai K., Pang J.C., et al. Clinical significance of vasculogenic mimicry in human gliomas. JNeurooncol 2011, 105:173-179.